Recently, Scythian Biosciences, in partnership with the University of Miami Miller School of Medicine, announced their positive preclinical data on the efficacy and safety of cannabis for a mild to moderate traumatic brain injury (TBI). The Canadian research firm announced that the cognitive function of their rodent subjects increased with CBD alone and with the terpene-based cannabinoid HU-211 alone. Similarly, combining the two medicines didnt show any adverse effects.
This is the first step in the systematic evaluation of how CBD can possibly treat the neurological complications involved in a TBI or concussion. A TBI can often lead to significant behavioral, cognitive, and physical changes, and these researchers are hoping that combination cannabinoid therapies can help mitigate these changes. As many of the research team involved in the preclinical study noted, this is only the beginning, and much more research is needed to find out how this plant can further serve the field of neurological medicine.
“There needs to be more systematic research in this field in order to study the neuroprotective properties of CBD and to improve treatment for those sustaining mild to moderate TBI and concussion. We are excited by these results; although in the early stages, shows positive preclinical work which shows promise to hopefully lead us to future clinical trials, said Gillian A. Hotz, Ph.D., University of Miami Miller School of Medicine, Research Professor, Department of Neurological Surgery.